This section contains a few examples and is not an exhaustive list. Some DSM panel members have had financial ties with pharmaceutical industry. Follow these links for research examples in this area: https://pubmed.ncbi.nlm.nih.gov/16636630/ OR https://pubmed.ncbi.nlm.nih.gov/19401623/ Some argue that co-operation is to be expected between industry and researchers. Others argue this is a potential conflict of interest and that DSM panel members should be obligated to disclose any ties they have. In the DSM5 many changes are controversial. Asperger's syndrome was removed and placed under the umbrella of autism spectrum disorder despite the syndrome not having a delay in language or congitive development. The threshold to be diagnosed with generalised anxiety disorder was lowered. Some argue this could increase the risk of misdiagnosis with everyday worries. A lot of research was done by neurotypical researchers processed by neurotypical reviewers and does not control for potential neurotypial biases. The DSM can be a useful aid for trained experts but it is not perfect.